A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Inclusion Criteria (Phase 1, Molecular Profiling): * Have available archival tumor tissue or fresh tumor specimen from diagnostic histological tissue for molecular profiling. * Histological or cytological proof of malignant salivary gland tumor * ECOG performance score 0-2 * Documented evidence of recurrent or metastatic disease Inclusion Criteria (Phase 2, Treatment): * Interpretable result of molecular profiling in the molecular profiling phase of this study * Advanced recurrent or metastatic salivary gland cancer for which no curative therapy exists * Evidence of clinical or radiological disease progression at the time of study treatment * At least one measurable target lesion as defined by RECIST 1.1 * Must have adequate hematological, liver, renal and cardiac function * No concomitant use of drugs which may prolong QTc interval * No history of serious cardiac illness * No serious medical conditions that might be aggravated by treatment or limit compliance. * Central nervous system metastases are permitted provided these are clinically stable * Able to take oral medication and have no evidence of bowel obstruction, infectious/inflammatory bowel disease * No other active malignancy at any other site * 18 years of age or older * Measureable disease as defined by RECIST v1.1 * Not receiving any other concurrent investigational agent * If the matched treatment is in the context of another phase I trial, the eligibility criteria of the enrolled trial will be used instead of…